A Multicenter Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain

Postoperative Pain Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, and Parallel Groups, Placebo-controlled Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02254525
• Other study ID #: BIBEC02
• Status: Terminated
• Phase: Phase 3
• First received: September 25, 2014
• Last updated: October 1, 2014
• Start date: May 2012
• Est. completion date: July 2014

Study information

• Verified date: September 2014
• Source: Biomendi S.A.U.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to study the efficacy of intravenous administration of ibuprofen compared to placebo in patients with postoperative pain and evaluate its tolerability and safety profile.

Description:

This is a phase III, national, multicenter, randomized, double-blind, parallel groups, and placebo-controlled.

Patients will be randomized to receive either ibuprofen or placebo. Stratified randomization will be used to assign eligible patients to a stratum according to type of surgery and centre. Randomization sequence will be generated in the coordinating centre.

Blinding of the patient and study personnel evaluating response will be warranted by adequate drug labelling.

All patients will receive morphine administered by patient controlled analgesia (PCA) following a similar schedule in all centres: 1 mg bolus dose with a close time of 5 min and a maximum of 10 mg in an hour and a maximum of 30 mg in 4 hours.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 231
• Est. completion date: July 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Men or women between 18 and 80 years old.

2. Being scheduled for elective single surgical site orthopaedic surgery (hip or knee joint replacement, corsed ligaments, column or shoulder surgery), or abdominal surgery (inguinal hernia, cholecystectomy, eventration or hiatus hernia)

3. Being scheduled for general anaesthesia or regional anesthesia without regional analgesia after surgery.

4. Having anticipated need for postoperative narcotic analgesia administered by patient controlled analgesia (PCA).

5. Expected to stay at the hospital for at least 24 h.

6. Providing written informed consent for participating in this study.

Exclusion Criteria:

1. Use of NSAID within 12 hours prior to the first planned dose.

2. Taking oral anticoagulants, lithium, combination of ACE inhibitors, furosemide or aspirin.

3. Anaemia (haemoglobin <10 g/dl) and/or history or evidence of asthma or heart failure.

4. History of allergy or hypersensitivity to any component of IV ibuprofen, aspirin or aspirin related products, NSAID or COX-2 inhibitors.

5. Pregnant or nursing.

6. Weight less than 40 kg.

7. History of severe head trauma that required hospitalization, intracranial surgery or stroke within the previous 30 days, or any history of intracerebral arteriovenous malformation, cerebral aneurism or CNS mass lesion.

8. History of congenital bleeding diathesis or any active clinically significant bleeding or underlying platelet dysfunction.

9. Gastrointestinal bleeding that required medical intervention.

10. Platelet count less than 80.000 determined within the 28 days prior to surgery.

11. Pre-existing dependence on narcotics or receiving chronic treatment with opioids.

12. Severe renal failure (calculated creatinine clearance < 60 ml/min).

13. Liver failure, ALAT or ASAT >3 times upper limit of normality, or bilirubin >2 g/dl.

14. Diagnosed of Bowel Inflammatory Disease.

15. Not able to understand the requirements of the study, or to abide by the study restrictions or to return for the required assessments.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pain, Postoperative
• Postoperative Pain

Intervention

Drug:
• Intravenous ibuprofen
Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose. All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.
• Saline solution
Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose. All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.

Locations

Country	Name	City	State
Spain	Hospital de Cruces	Barakaldo	Vizcaya
Spain	Complejo Hospitalario Universitario de A Coruña	La Coruña
Spain	Hospital Arnau de Vilanova de Lleida	Lleida
Spain	Fundación Jiménez Díaz	Madrid
Spain	Hospital 12 de Octubre	Madrid
Spain	Hospital de Montepríncipe	Madrid
Spain	Hospital La Princesa	Madrid
Spain	Hospital de Móstoles	Móstoles	Madrid
Spain	Clínica Universitaria de Navarra	Pamplona
Spain	Hospital Virgen de la Salud	Toledo
Spain	Hospital La Fe	Valencia
Spain	Hospital Clínico de Valladolid	Valladolid
Spain	Hospital Xeral Cíes de Vigo	Vigo	Pontevedra

Sponsors (2)

Lead Sponsor	Collaborator
Biomendi S.A.U.	Pivotal S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the efficacy of intravenous ibuprofen for the management of postoperative pain in comparison to placebo	The primary efficacy endpoint will be the reduction in total morphine use in the first 24 hours post- surgery as compared to placebo.	First 24 hours post- surgery	No
Secondary	Secondary efficacy endpoints	- Consumption of morphine in the first 48 h (and 72) hours post- surgery.	From 0 hours to 72 hours post- surgery	No
Secondary	Secondary efficacy endpoints	- Pain intensity at rest and with movement measured with the eleven points visual analogue scale (VAS), at 1 and 3 hours and every 6 hours thereafter up to hour 24 h, and then every 8 h up to 6 hour after the last ibuprofen dose.	From 0 hours to 72 hours post- surgery	No
Secondary	Secondary efficacy endpoints	- Ramsay-Hunt sedation scale.	From 0 hours to 72 hours post- surgery	No
Secondary	Secondary efficacy endpoints	- Time to first subsequent narcotic analgesia (or time to treatment failure).	From 0 hours to 72 hours post- surgery	No
Secondary	Secondary efficacy endpoints	- Number of doses of morphine and number of attempts of dosing at PCA	From 0 hours to 72 hours post- surgery	No
Secondary	Secondary tolerability and safety endpoints	- Report of adverse events (AEs) during the study	From 0 hours to 72 hours post- surgery	Yes
Secondary	Secondary tolerability and safety endpoints	- Local reactions due to IV infusion (pain, erythema, phlebitis)	From 0 hours to 72 hours post- surgery	Yes
Secondary	Secondary tolerability and safety endpoints	- Vital signs (heart rate, blood pressure, temperature) at 1, 3, 6 hour after the initial dose and every 8 hours thereafter.	From 0 hours to 72 hours post- surgery	Yes
Secondary	Secondary tolerability and safety endpoints	- Routine laboratory tests (chemistry, haematology and coagulation) at baseline and within 24 hours after the last dose.	From 0 hours to 72 hours post- surgery	Yes